The magnitude of the survival benefit associated with anti-PD-1/PD-L1 combinational therapy in the low PD-L1 population was moderate, and the survival benefit was mainly observed in specific tumor types, including NSCLC, SCLC, ESCC, melanoma and NPC. This evidence concerns the gene CD274 and melanoma.